All Updates

All Updates

icon
Filter
M&A
Takeda acquires Nimbus Therapeutics’s subsidiary; pays USD 4 billion upfront
AI Drug Discovery
Feb 9, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Feb 9, 2023

Takeda acquires Nimbus Therapeutics’s subsidiary; pays USD 4 billion upfront

M&A

  • Japanese pharma company Takeda Pharmaceuticals has acquired 100% of the common shares of American AI biotechnology company Nimbus Therapeutics’s fully owned subsidiary Nimbus Lakshmi and its Tyrosine kinase 2 (TYK2) (intracellular enzyme) program. The transaction was previously announced in December 2022. 

  • Following the acquisition, Nimbus’ drug candidate NDI-034858 for psoriasis will be renamed to “TAK-279”. Takeda will be solely responsible for the development of the candidate and a Phase 3 clinical trial is slated to be conducted in 2023. The acquisition is expected to expand and strengthen Takeda’s late-stage pipeline.

  • As part of the transaction, Nimbus will receive USD 4 billion upfront and USD 1 billion each for two milestones–achieving net sales of USD 4 billion and USD 5 billion for products developed as part of the TAK-279 program. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.